Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 2/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570291 | 0.89 | NT5E (0.32) | ABCC8KCNJ11NT5EALDH1A1LMNA | |
| SCHEMBL4265026 | 0.80 | NT5E (0.33) | ABCC8KCNJ11NT5EALDH1A1LMNA | |
| SCHEMBL7077604 | 0.79 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL8286614 | 0.74 | ABCC8 (0.50) | ABCC8KCNJ11NT5EALDH1A1LMNA | |
| SCHEMBL7075417 | 0.73 | MEN1 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7079077 | 0.72 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL7492919 | 0.71 | ADRA2A (0.31) | — | |
| SCHEMBL7954682 | 0.71 | CXCR2 (0.50) | NT5ECXCR2 | |
| SCHEMBL7593117 | 0.71 | ABCC8 (0.42) | ABCC8KCNJ11TSHRSMN1; SMN2 | |
| SCHEMBL7563898 | 0.71 | ALDH1A1 (0.34) | ABCC8KCNJ11ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | claimed |
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | ABCC8 2284/4885KCNJ11 1510/4885NT5E 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.